Glycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
HF Acquisition Co LLC is recalling Glycopyrrolate Injection 0.2mg/mL due to a label mix-up affecting specific lots distributed in Texas, Arizona, and California.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III drug recall involving a labeling error with no reported illnesses or injuries. Per the severity rubric, minor labeling errors are typically scored as Moderate (2).
Plain-English summary
HF Acquisition Co LLC is recalling Glycopyrrolate Injection, USP 0.2mg/mL in 1mL vials because of a label mix-up. The recalled product is Lot #2205095.1, which expires July 31, 2024. The recall involves 9 boxes containing 25 vials each.
The product was distributed to Texas, Arizona, and California. Healthcare facilities and patients who have this product should contact HF Acquisition Co LLC or their distributor for instructions on return and replacement.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- HF Acquisition Co LLC
- Hazard
- label-mix-up
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 2205095.1
- Exp. Date 7/31/2024
Distribution
Distributed in 3 states:
- AZ
- CA
- TX
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Oral Solution Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-02-04
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate injection recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighGlycopyrrolate Injection Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Glycopyrrolate Injection Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27